Literature DB >> 13398478

The plasma disappearance, excretion, and tissue distribution of cobalt 60 labelled vitamin B12 in normal subjects and patients with chronic myelogenous leukemia.

H F CORBUS, A MILLER, J F SULLIVAN.   

Abstract

Entities:  

Keywords:  LEUKEMIA, MYELOCYTIC/metabolism; VITAMIN B12/metabolism

Mesh：

Substances：

Year:  1957        PMID： 13398478      PMCID： PMC1087292          DOI： 10.1172/JCI103404

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  14 in total

1.  The plasma clearance and urinary excretion of parenterally administered 58Co B12.

Authors:  D L MOLLIN; W R PITNEY; S J BAKER; J E BRADLEY
Journal:  Blood       Date:  1956-01       Impact factor: 22.113

2.  The serum vitamin B12 concentration in pernicious anemia.

Authors:  A A LEAR; J W HARRIS; W B CASTLE; E M FLEMING
Journal:  J Lab Clin Med       Date:  1954-11

3.  Vitamin B12 content of normal and leukaemic leucocytes.

Authors:  J W THOMAS; B B ANDERSON
Journal:  Br J Haematol       Date:  1956-01       Impact factor: 6.998

4.  Serum concentrations of vitamin B12 in patients suffering from leukemia.

Authors:  M F BEARD; W R PITNEY; E H SANNEMAN
Journal:  Blood       Date:  1954-08       Impact factor: 22.113

5.  Serum vitamin B12 concentrations in leukaemia and in some other haematological conditions.

Authors:  D L MOLLIN; G I ROSS
Journal:  Br J Haematol       Date:  1955-04       Impact factor: 6.998

6.  Observations on the bound form of vitamin B12 in human serum.

Authors:  W R PITNEY; M F BEARD; E J VAN LOON
Journal:  J Biol Chem       Date:  1954-03       Impact factor: 5.157

7.  The occurrence of growth factors for Lactobacillus leichmannii; Streptococcus faecalis and Leuconostoc citrovorum in the tissues of pernicious anaemia patients and controls.

Authors:  R H GIRDWOOD
Journal:  Biochem J       Date:  1952-09       Impact factor: 3.857

8.  Biochemical studies on leucocytes. I. Phosphatase activity in health, leucocytosis, and myelocytic leucemia.

Authors:  W N VALENTINE; W S BECK
Journal:  J Lab Clin Med       Date:  1951-07

9.  Vitamin B12 assay in body fluids using Euglena gracilis.

Authors:  G I M ROSS
Journal:  J Clin Pathol       Date:  1952-08       Impact factor: 3.411

10.  Studies on the histamine content of blood, with special reference to leukemia, leukemoid reactions and leukocytoses.

Authors:  W N VALENTINE; M L PEARCE; J S LAWRENCE
Journal:  Blood       Date:  1950-07       Impact factor: 22.113
View more
  7 in total

1.  [Problem of radiation dosage in the Schilling urine excretion test with Co60-vitamin B12].

Authors:  G MULLER; P COSTAMIS; W PRIBILLA; W MAURER
Journal:  Klin Wochenschr       Date:  1959-05-15

2.  [Studies on vitamin B12 metabolism with intravenously administered Co58-labelled vitamin B12].

Authors:  W SCHWARTZKOPFF; A PAPAGEORGIOU; H G WOLTERS
Journal:  Blut       Date:  1961-09

3.  Co58B12 absorption, plasma transport and excretion in patients with myeloproliferative disorders, solid tumors and non-neoplastic diseases.

Authors:  I B WEINSTEIN; D M WATKIN
Journal:  J Clin Invest       Date:  1960-11       Impact factor: 14.808

4.  The plasma vitamin B12 binding substance. I. Its detection in the seromucoid fraction of plasma from normal subjects and patien with chronic myelocytic leukemia.

Authors:  I B WEINSTEIN; S M WEISSMAN; D M WATKIN
Journal:  J Clin Invest       Date:  1959-11       Impact factor: 14.808

5.  Electrophoretic studies of the vitamin B12-binding protein of normal and chronic myelogenous leukemia serum.

Authors:  A MILLER; J F SULLIVAN
Journal:  J Clin Invest       Date:  1959-12       Impact factor: 14.808

6.  The plasma disappearance of intravenously administered cobalt 58 vitamin B12.

Authors:  C A HALL
Journal:  J Clin Invest       Date:  1960-08       Impact factor: 14.808

7.  The in vitro binding of cobalt 60 labeled vitamin B12 by normal and leukemic sera.

Authors:  A MILLER
Journal:  J Clin Invest       Date:  1958-04       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.